ALX Oncology Holdings announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology. ALX Oncology intends to use the net proceeds from the offering to fund ongoing development of evorpacept, including clinical trials targeting market expansion, and for working capital and general corporate purposes. Piper Sandler and Cantor are acting as the joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology Announces Pricing of Public Offering
- ALX Oncology Announces Proposed Public Offering
- ALX Oncology price target raised to $17.50 from $16 at H.C. Wainwright
- ALX Oncology’s evorpacept shows efficacy in Phase 2 gastric cancer trial
- ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer